In a report issued on June 22, Michael Dahl from RBC Capital maintained a Hold rating on DR Horton (DHI – Research Report), with a price target of $70.00. The company’s shares closed last Friday at $67.69, close to its 52-week low of $59.25.
According to TipRanks.com, Dahl is a 4-star analyst with an average return of 5.2% and a 53.2% success rate. Dahl covers the Consumer Goods sector, focusing on stocks such as Skyline Champion, Taylor Morrison, and Toll Brothers.
DR Horton has an analyst consensus of Moderate Buy, with a price target consensus of $90.46, which is a 33.0% upside from current levels. In a report issued on June 14, CFRA also downgraded the stock to Hold with a $80.00 price target.
Based on DR Horton’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $8 billion and net profit of $1.44 billion. In comparison, last year the company earned revenue of $6.45 billion and had a net profit of $930 million.
Based on the recent corporate insider activity of 86 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1978, Texas-based D.R. Horton, Inc. is a homebuilding company that is engaged in the construction and sale of single-family homes through its diverse brand portfolio that includes D.R. Horton, Emerald Homes, Express Homes and Freedom Homes.
Read More on DHI: